MeiraGTx (MGTX) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Replimune Group (REPL) has outperformed MeiraGTx (MGTX) over the past year, gaining 183.9% versus a gain of 27.4%. Over five years, MGTX leads with a -24.2% price change compared with -56.2% for REPL. Replimune Group is the larger company by market cap ($1.24 billion vs $1.04 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | REPL |
|---|---|---|
| Share price | $10.82 | $13.20 |
| Market cap | $1.04B | $1.24B |
| 1-day change | +2.08% | -0.38% |
| YTD return | +36.10% | +35.80% |
| 1-year return | +27.44% | +183.87% |
| 5-year return | -24.23% | -56.22% |
| P/E ratio (TTM) | 12.44 | — |
| EPS (TTM) | $0.87 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.35 | $16.33 |
| 52-week low | $6.62 | $1.50 |
| Distance from 52-week high | -29.51% | -19.17% |
| Average volume | 773.85K | 4.20M |
| Shares outstanding | 96.04M | 94.22M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed MGTX by 156.4 percentage points over the past year.
MGTX vs REPL FAQ
Which is bigger, MeiraGTx or Replimune Group?
Replimune Group (REPL) is larger, with a market capitalization of $1.24B compared with $1.04B for MeiraGTx (MGTX).
Which stock has performed better over the past year, MGTX or REPL?
REPL returned +183.87% over the past 12 months, compared with +27.44% for MGTX (price return, excluding dividends). Past performance does not predict future results.
Are MeiraGTx and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.